Companies / BOC Sciences / Bamlanivimab
BOC Sciences

Bamlanivimab | BOC Sciences

Bamlanivimab is a monoclonal antibody granted Emergency Use Authorization (EUA) in November 2020 by FDA for COVID-19 therapy. Bamlanivimab is directed against the spike protein of SARS-CoV-2, designed to block the virus' attachment and entry into human cells.

Reviews


No reviews yet

ABOUT THE COMPANY

BOC Sciences specializes in small molecule synthesis, biosynthesis, purification, and characterization. It provides a wide range of research chemicals and biochemicals, including inhibitors, building blocks, carbohydrates, nucleosides, nucleotides, GMP Products, impurities and metabolites, APIs, natural compounds, ADCs, stem cell molecules and chiral compounds.